BioMarin Adds Board Member
This article was originally published in Scrip
BioMarin Pharmaceutical Inc. has appointed former chair and CEO of Allergan, David Pyott, to its board of directors. Pyott was CEO of Allergan from 1998 to 2015 and was recognized by the Harvard Business Review as one of 'The 100 Best Performing CEOs in the World'. Prior to Allergan he was the head of Novartis nutrition division and a member of the executive committee of Novartis AG. Currently Pyott is lead director and board member of Avery Dennison Corporation and a board member of Alnylam Pharmaceuticals Inc.
You may also be interested in...
How to make the most of the wealth of raw data in pharmaceutical R&D is an increasing challenge for the industry. The digital revolution is already having an impact in areas like clinical trials, and pharma is also starting to embrace new technologies in drug discovery.
Technology advancement has brought a wave of change in healthcare, with an increasing number of key pharma players now recognizing the potential of digital – particularly in clinical trials.
This week's roundup includes high-level appointments by Five Prime Therapeutics, Depomed and Gilead Sciences and board appointments by Verseon, Arix Bioscience, and Corbus Pharmaceuticals.